Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart

The U.S. accounts for 27% of the world’s coronavirus vaccine production, but 0% of the global supply beyond its own borders. Critics and allies alike say it’s time for that to change.

Why it matters: China has gotten a head start on vaccine diplomacy, sending millions of doses all over the globe, including to Latin America. Experts say it’s in America’s interests to compete in the race to vaccinate the world, and the calls to start doing so are getting louder.

Driving the news: The Biden administration took a tentative first step last week, offering around 4 million total doses of the Oxford/AstraZeneca vaccine — which isn’t authorized for use in the U.S. — to Mexico and Canada.

  • The administration has also pledged $4 billion to the global COVAX initiative and more still to help increase supplies to Asia. But it’s holding tight to virtually every dose produced in the U.S.

"We're going to have excess supply," said Zeke Emanuel, vice provost for global initiatives at the University of Pennsylvania, who was a member of Biden’s coronavirus task force during the transition.

  • "It would be unethical, and it would be a diplomatic and strategic mistake, to say we need to build up a buffer of 100 million doses while China and Russia are selling to people and saying, you know, 'You guys count,'" he tells Axios.

Where it stands: China has made about 33% of all the vaccine doses in the world. It’s exporting about 62% of its doses to other countries, which it can do, in part, because it largely has the virus under control domestically.

  • The U.S. is the second-biggest producer, at 27%, but its bulk contracts with manufacturers keep doses produced in the U.S. from leaving.
  • The global supply of the Pfizer/BioNTech vaccine is coming from the EU, which is exporting 48% of its production, vs. 0% from the U.S. according to Airfinity, a science information and analytics company.
  • Moderna is using its European facilities to supply Canada with doses, because all doses produced at U.S. sites are going toward the 300 million the U.S. has purchased.

"It is a de facto ban" on exports, one European diplomat told Axios with some exasperation.

  • The diplomat acknowledged that the U.S. had made early investments to ramp up supply, and thus should expect priority access — but expressed surprise that there was so little domestic opposition to Biden's "Americans first" approach.
  • Leaders in Brussels are vigorously debating whether to tighten controls on exports from the EU, accusing the U.S. and U.K. of accepting imports while failing to reciprocate.
  • Adar Poonawalla, the CEO of the Serum Institute of India, says the Biden administration’s applications of the Defense Production Act to steer supplies toward vaccine manufacturing in the U.S. are causing shortages elsewhere. India is exporting about 65% of the doses made there.
Expand chart
Note: This map represents the total number of vaccines administered, not people vaccinated; Data: Our World in Data; Map: Danielle Alberti/Axios

What's next: Most of the other major players will still be facing huge domestic needs long after the U.S. has secured enough doses for its entire adult population. That means the tap could soon be flipped on, allowing U.S.-made vaccines to flow all over the world.

  • Emanuel expects that tipping point to come in June or July.
  • Krishna Udayakumar, director of the Duke Global Health Innovation Center, said the U.S. could become the top exporter by the second half of the year.
  • The U.S. has already purchased enough doses of approved vaccines to vaccinate 500 million people — more than enough for its entire adult population (roughly 250 million people) with plenty to spare for children and potential booster shots. Then there are 410 million additional doses from AstraZeneca and Novavax, which could be approved by May.

“The question really is, what is the threshold that’s going to satisfy the administration enough to allow the exporting of those doses?” Udayakumar says.

Go deeper: Vaccines and stimulus pave the way for a big, uneven global recovery

Go deeper

Study: Social media giants failing to remove most antisemitic posts

Facebook CEO Mark Zuckerberg speaking virtually during a March House Energy and Commerce Subcommittees hearing on a laptop computer in Tiskilwa, Illinois. Photo: Daniel Acker/Bloomberg via Getty Images

Five social media giants failed to remove 84% of antisemitic posts in May and June — and Facebook performed the worst despite announcing new rules to tackle the problem, a new report finds.

Driving the news: The Center for Countering Digital Hatred (CCDH) notes in its study that it reported 714 posts containing "anti-Jewish hatred" to Facebook, Twitter, Instagram, Youtube and TikTok — which were collectively viewed 7.3 million times. These "clearly violated" company policies, according to the CCDH.

Ina Fried, author of Login
Updated 2 hours ago - Sports

Transgender weightlifter Laurel Hubbard: "It gets better"

New Zealand weightlifter Laurel Hubbard became the first openly transgender woman to compete in the Olympics. Ina Fried/Axios

Laurel Hubbard, speaking to reporters after becoming the first openly transgender woman to compete in the Olympics, on Tuesday expressed gratitude for the opportunity to compete as an athlete and convince transgender people to work through adversity.

What she's saying: "All I have ever really wanted as an athlete is just to be regarded as an athlete," Hubbard, said in response to a question from Axios. "I suppose the thing I have been so grateful here in Tokyo is just being given those opportunities to just go through life as any other athlete."

Amazon may have violated law in Alabama warehouse vote, NLRB says

The Amazon BHM1 fulfillment center in Bessemer, Alabama. Photo: Patrick T. Fallon/AFP via Getty Images

Amazon warehouse workers in Bessemer, Alabama, should hold a new election to determine whether to unionize with the Retail, Wholesale and Department Store Union, the National Labor Relations Board said in a preliminary finding Monday.

Details: The e-commerce giant may have illegally interfered in a mail-in election tallied in April on whether workers at the plant should unionize, per a statement from an NLRB hearing officer assigned to the case. Amazon said it would appeal any ruling stipulating that a second vote should take place.